- Emcure Pharmaceuticals' API manufacturing facility in Maharashtra underwent a week-long USFDA cGMP inspection, resulting in two Form 483 observations. - Relonchem Limited, a Marksans Pharma subsidiary, secured UK marketing authorization for its combination pain relief product containing Ibuprofen 200mg and Paracetamol 500mg. - The dual-action pain relief medication will be marketed under Bell's Healthcare brand, expanding Relonchem's presence in the UK pharmaceutical market.

Feb 27, 2025

返回机构列表

MARKSANS PHARMA LIMITED

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（3）

An Open Label Single Dose Oral Bioequivalence Study Comparing Guaifenesin and Dextromethorphan Hydrobromide Extended Release Tablets 1200 mg by 60 mg in Healthy Adult Human Subjects Under Fasting Conditions

A Single Dose Oral Bioequivalence Study Comparing Guaifenesin and Dextromethorphan Hydrobromide Tablets 1200 mg / 60 mg in Healthy Adult Human Subjects Under Fed Conditions

An Open Label Single Dose Two Period Oral Bioequivalence Study Comparing Guaifenesin And Dextromethorphan Hydrobromide Extended Release Tablets 1200 mg/ 60 mg In Healthy Adult Human Subjects Under Fed Conditions

药物批准

按机构分类的批准

近期批准

资讯

FDA Inspection of Emcure's API Facility Results in Form 483; Relonchem Gains UK Approval for Pain Relief Combination